Immunocore announces first patient dosed in the Phase 1 trial of IMC-S118AI – its first tissue-specific autoimmune candidate – for patients with type 1 diabetes

Colin Dayan, Professor of Diabetes and Metabolism, Department of Immunology and Immunotherapy, University of Birmingham

“This is a very exciting development for the type 1 diabetes community. We know that T1D is not a systemic autoimmune disease; it is exquisitely targeted to the insulin-making beta cells which comprise just 1% of the pancreas”

Colin Dayan, Professor of Diabetes and Metabolism, Department of Immunology and Immunotherapy, University of Birmingham

“In T1D, we need a high degree of safety for tissue-specific therapies to be chosen over insulin that we have used for over 100 years. This targeted immune therapy specific for beta cells, now in a Phase 1 trial could offer us an effective and well-tolerated treatment option, if supported by clinical data.”

Mohammed Dar, Executive Vice President, Clinical Development and Chief Medical Officer, Immunocore

“With our modular bispecific platform already validated in oncology and with initial proof of concept in infectious disease indications, we are now focused on evaluating this technology in a third therapeutic area. Our goal is to leverage a tissue-targeted approach to protect beta cells and preserve insulin secretion in patients.”